55 related articles for article (PubMed ID: 32080761)
1. Proposal to distinguish HER2-low from HER2-normal breast cancer by in situ hybridisation.
Chen YY; Yang CF; Hsu CY
J Clin Pathol; 2023 Nov; 76(11):753-756. PubMed ID: 37852628
[TBL] [Abstract][Full Text] [Related]
2. Novel approach to HER2 quantification using phosphor-integrated dots in human breast invasive cancer microarray.
Saito N; Matsuo T; Tsuda H; Yokota H; Okada H
PLoS One; 2024; 19(5):e0303614. PubMed ID: 38748758
[TBL] [Abstract][Full Text] [Related]
3. [Quantitative HER2 mRNA assay in breast cancer with HER2 immunohistochemistry 0].
Sun MC; Wu SF; Cai YM; Liu YY; Li KM; Zhao DC; Zeng X
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):464-469. PubMed ID: 38678327
[No Abstract] [Full Text] [Related]
4. HER2 evaluation for clinical decision making in human solid tumours: pearls and pitfalls.
Zhang H; Finkelman BS; Ettel MG; Velez MJ; Turner BM; Hicks DG
Histopathology; 2024 Jul; 85(1):3-19. PubMed ID: 38443321
[TBL] [Abstract][Full Text] [Related]
5. "Analysis of immunohistochemical expression of epidermal growth factor receptor in oral squamous cell carcinoma using tissue microarray technology and whole sections:" A comparative study.
Sajjanar M; Sajjan P; Puranik RS; Vanaki S; Jayanth V; Naik P
J Oral Maxillofac Pathol; 2020; 24(3):499-504. PubMed ID: 33967487
[TBL] [Abstract][Full Text] [Related]
6. Label-Free Virtual HER2 Immunohistochemical Staining of Breast Tissue using Deep Learning.
Bai B; Wang H; Li Y; de Haan K; Colonnese F; Wan Y; Zuo J; Doan NB; Zhang X; Zhang Y; Li J; Yang X; Dong W; Darrow MA; Kamangar E; Lee HS; Rivenson Y; Ozcan A
BME Front; 2022; 2022():9786242. PubMed ID: 37850170
[TBL] [Abstract][Full Text] [Related]
7. The Vitamin D Receptor as a Prognostic Marker in Breast Cancer-A Cohort Study.
Huss L; Gulz-Haake I; Nilsson E; Tryggvadottir H; Nilsson L; Nodin B; Jirström K; Isaksson K; Jernström H
Nutrients; 2024 Mar; 16(7):. PubMed ID: 38612962
[TBL] [Abstract][Full Text] [Related]
8. Potential interplay between tumor size and vitamin D receptor (VDR) polymorphisms in breast cancer prognosis: a prospective cohort study.
Lindgren H; Ademi D; Godina C; Tryggvadottir H; Isaksson K; Jernström H
Cancer Causes Control; 2024 Jun; 35(6):907-919. PubMed ID: 38351438
[TBL] [Abstract][Full Text] [Related]
9. HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Popović M; Silovski T; Križić M; Dedić Plavetić N
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175916
[TBL] [Abstract][Full Text] [Related]
10. TMA-Mate: An open-source modular toolkit for constructing tissue microarrays of arbitrary layouts.
Pazaitis N; Kaiser A
HardwareX; 2023 Jun; 14():e00419. PubMed ID: 37128356
[TBL] [Abstract][Full Text] [Related]
11. Caveolin-1 genotypes as predictor for locoregional recurrence and contralateral disease in breast cancer.
Godina C; Tryggvadottir H; Bosch A; Borgquist S; Belting M; Isaksson K; Jernström H
Breast Cancer Res Treat; 2023 Jun; 199(2):335-347. PubMed ID: 37017811
[TBL] [Abstract][Full Text] [Related]
12. Improving HER2 testing reproducibility in HER2-low breast cancer.
Sajjadi E; Venetis K; Ivanova M; Fusco N
Cancer Drug Resist; 2022; 5(4):882-888. PubMed ID: 36627898
[TBL] [Abstract][Full Text] [Related]
13. Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer.
Godina C; Indira Chandran V; Barbachowska M; Tryggvadottir H; Nodin B; Visse E; Borgquist S; Jirström K; Isaksson K; Bosch A; Belting M; Jernström H
Transl Oncol; 2022 Aug; 22():101464. PubMed ID: 35660849
[TBL] [Abstract][Full Text] [Related]
14. Impact of combining vitamin C with radiation therapy in human breast cancer: does it matter?
Khazaei S; Nilsson L; Adrian G; Tryggvadottir H; Konradsson E; Borgquist S; Isaksson K; Ceberg C; Jernström H
Oncotarget; 2022; 13():439-453. PubMed ID: 35222809
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of tumor-specific insulin-like growth factor binding protein 7 (IGFBP7) levels in breast cancer: a prospective cohort study.
Godina C; Khazaei S; Tryggvadottir H; Visse E; Nodin B; Jirström K; Borgquist S; Bosch A; Isaksson K; Jernström H
Carcinogenesis; 2021 Nov; 42(11):1314-1325. PubMed ID: 34606580
[TBL] [Abstract][Full Text] [Related]
16. The Prognostic Impact of Intratumoral Aryl Hydrocarbon Receptor in Primary Breast Cancer Depends on the Type of Endocrine Therapy: A Population-Based Cohort Study.
Tryggvadottir H; Sandén E; Björner S; Bressan A; Ygland Rödström M; Khazaei S; Edwards DP; Nodin B; Jirström K; Isaksson K; Borgquist S; Jernström H
Front Oncol; 2021; 11():642768. PubMed ID: 34094928
[TBL] [Abstract][Full Text] [Related]
17. Patient Characteristics Influence Activated Signal Transducer and Activator of Transcription 3 (STAT3) Levels in Primary Breast Cancer-Impact on Prognosis.
Nilsson L; Sandén E; Khazaei S; Tryggvadottir H; Nodin B; Jirström K; Borgquist S; Isaksson K; Jernström H
Front Oncol; 2020; 10():1278. PubMed ID: 32850390
[No Abstract] [Full Text] [Related]
18. Re-evaluation of HER2 status in 606 breast cancers-gene protein assay on tissue microarrays versus routine pathological assessment.
Sandén E; Khazaei S; Tryggvadottir H; Borgquist S; Isaksson K; Jirström K; Jernström H
Virchows Arch; 2020 Aug; 477(2):317-320. PubMed ID: 32080761
[TBL] [Abstract][Full Text] [Related]
19. The assessment of HER2 status in breast cancer: the past, the present, and the future.
Nitta H; Kelly BD; Allred C; Jewell S; Banks P; Dennis E; Grogan TM
Pathol Int; 2016 Jun; 66(6):313-24. PubMed ID: 27061008
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
